Sanofi, RadioMedix, and Orano Med Announce Licensing Agreement for Next-Generation Radioligand Medicine Targeting Rare Cancers
As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a US clinical-stage biotechnology company developing radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT) against unmet medical needs in cancer, and Orano Med, a French clinical-stage biotechnology company, […]
RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers
Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug RadioMedix and Orano Med, two clinical stage radiopharmaceutical companies, today announced that the last patient has been dosed in the Phase II trial of the targeted alpha emitter therapy, 212Pb-DOTAMTATE (AlphaMedix™). This trial is being conducted to evaluate the safety and effectiveness of AlphaMedix™ […]
RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in gastroenteropancreatic neuroendocrine tumors
First Targeted Alpha Therapy to receive a Breakthrough Therapy Designation RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Phase Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute at the US National Institutes of Health . The grant supports Phase I/II […]
RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharmaceuticals Inc.
Izabela Tworowska, RadioMedix CSO, selected as Semi-Finalists of 2021 Women’s Venture Competition! The AIM-HI Accelerator Fund just announced 10 semi-finalists for the 2021 Women’s Venture Competition! These oncology companies have been selected from among an exceptional pool of applications submitted globally by women scientist-entrepreneurs. Decision making was led by a selection committee comprised of world-class key opinion […]
